Impact of Brazil on the Pharmaceutical Industry – Thematic Intelligence
Brazil Pharmaceutical Market Report Overview
Brazil is the largest pharmaceutical market in Central/Southern America and is the 12th largest in the world. Brazil is an untapped market for big pharma manufacturing, with domestic companies dominating the marketed products landscape. The domestic pharmaceutical companies will continue to grow due to favorable policies provided by the Brazilian government to promote domestic production of medicines. Furthermore, over the years, Brazil has elevated its infrastructure, scientific, and technological facilities and has created a sustainable strategy to promote drug discovery and other research activities.
The Brazil pharmaceutical industry thematic intelligence report provides an assessment of the major industry, and regulatory trends shaping the Brazil pharma industry.
Brazil Pharmaceutical Market Trends
The key trends impacting the Brazil pharmaceutical market are industry trends and regulatory trends.
Industry Trends: Brazil’s pharma industry has grown significantly over the last decade, driven by increasing household incomes, and it is well placed to provide medicines to other emerging markets in South America. The country also has a unified healthcare system known as Sistema Único de Saúde (SUS), the largest government-run public healthcare system in the world by number of beneficiaries. Moreover, Brazil is one of the major digital health markets of Latin America. Digitalization, eHealth, and telemedicine sectors are showing their ability to transition and adapt in Brazil, creating market potential opportunities, regardless of the fragmented market.
Regulatory Trends: Brazil has a decentralized, universal health system that is funded through taxes and contributions from federal, state, and municipal governments. The states or municipalities handle the administration and delivery of care. Additionally, the Chamber of Drug Market Regulations (CMED) creates the criteria to adjust and limit drug prices, adopts rules that encourage competition in the sector, monitors sales, and applies penalties for noncompliance with the rules.
To know more about the key trends impacting the Brazil pharmaceutical market, download a free report sample
Brazil Pharmaceutical Market Value Chain
Most pharmaceutical companies holding medicine licenses in both the public and private sectors commercialize their products in the Brazilian market through distributors. The federal, state, or municipal public administration entities have the authority to directly sell pharmaceutical products to the government.
Brazil has several national programs for the distribution of medicines that appear on RENAME, including oncology drugs, human immunodeficiency virus (HIV) infection, and chronic diseases such as schizophrenia, rheumatism, and arthritis.
To know more about the Brazil pharmaceutical market value chains, download a free report sample
Brazil Pharmaceutical Market Analysis
The Brazil pharmaceutical market was valued at $17.2 billion in 2021. Growth over the last decade has been driven by a growing population and increasing household incomes.
The most common deal types in the Brazilian pharmaceutical market are strategic alliances, mergers & acquisitions, contract service agreements, and capital raisings. The most common deal was strategic alliances, followed by M&As.
Brazil, with its progressive economic growth, stable political structure, expanding patient populations, and increasing governmental, private, and foreign investments, has favorable conditions to become an advanced pharmaceutical research center.
Brazil Pharmaceutical Revenue Forecast, 2015–30 ($ billions)
To know more about Brazil pharmaceutical revenue forecast, download a free report sample
Brazil Pharmaceutical Clinical Trial Analysis
The top therapy areas in the Brazil pharmaceutical market are oncology, central nervous system, infectious disease, respiratory, cardiovascular, metabolic disorders, and immunology among others. In 2020, the infectious disease therapy area saw a significant increase in clinical trials, due to the COVID-19 pandemic.
Of the top sponsors of clinical trials in Brazil, large international industry players are represented significantly more than domestic companies. Roche, Novartis, and AstraZeneca were the leading clinical trial sponsors in Brazil between 2019 and 2022YTD.
Clinical Trials by Top 10 Therapy Areas, 2019-2022
To know more about Brazil pharmaceutical therapy areas, download a free report sample
Brazil Pharmaceutical Marketed Products
The leading therapy area for marketed drugs in Brazil is central nervous system (CNS). Marketed drugs in Brazil mainly follow global trends. Brazil matches the global market in having CNS, infectious disease, and respiratory as its top three therapeutic areas.
Domestic pharmaceutical companies such as EMS, Germed Pharma, Legrand Pharma, Eurofarma, and Medley are the top five developers of marketed drugs in Brazil. Large international pharmaceutical companies, who have subsidiaries headquartered in Brazil, with a large presence in the Brazil market include Novartis, Sanofi, and Pfizer.
Marketed Drugs in Brazil by Therapy Area
For more insights into the marketed drugs in Brazil, download a free report sample
Brazil Pharmaceutical Pipeline Products
Most pipeline therapeutics are in Phase III and Phase II stages. There are only three companies with more than one pipeline product in Brazil. The leading pipeline biologic developers are the Butantan Institute and JCR Pharmaceuticals. All the Butantan Institutes’ products are in infectious disease, and one of JCR Pharmaceuticals’ drugs is in pre-registration.
The key molecule types in the COVID-19 pipeline in Brazil are subunit vaccine, small molecule, inactivated vaccine, cell therapy, monoclonal antibody, peptide, vaccine, and mRNA vaccine. In 2022, the subunit vaccine was the leading molecule type followed by small molecule and inactivated vaccine.
COVID-19 Pipeline Therapeutics by Molecule Type
For more insights into the COVID-19 pipeline therapeutics, download a free report sample
Brazil Pharmaceutical Market Report Overview
| Market Size (2021) | $17.2 billion |
| Forecast Period | 2022-2030 |
| Historical Period | 2015-2020 |
| Key Trends | Industry Trends and Regulatory Trends |
| Top Therapy Areas | Oncology, Central Nervous System, Infectious Disease, Respiratory, Cardiovascular, Metabolic Disorders, and Immunology |
| Key Molecule Types | Subunit Vaccine, Small Molecule, Inactivated Vaccine, Cell Therapy, Monoclonal Antibody, Peptide, Vaccine, and mRNA Vaccine |
Segments Covered in the Report
Brazil Pharmaceutical Therapy Areas Outlook
- Oncology
- Central Nervous System
- Infectious Disease
- Respiratory
- Cardiovascular
- Metabolic Disorders
- Immunology
Brazil Pharmaceutical Molecule Types Outlook
- Subunit Vaccine
- Small Molecule
- Inactivated Vaccine
- Cell Therapy
- Monoclonal Antibody
- Peptide
- Vaccine
- mRNA Vaccine
Scope
- It provides a detailed analysis of deals, clinical trials, marketed and pipeline products, and contract manufacturing.
- It also provides an overview of key regulatory and market access information, market drivers and barriers, and key players in the Brazilian pharma sector.
Reasons to Buy
- Identify the trends that are shaping the Brazilian pharma market and driving innovation, including key government policies and strategic initiatives.
- Identify key current and emerging players in the Brazil pharma market
- Develop in-licensing and out-licensing strategies, using a detailed overview of current deals
- Understand the challenges and strategies impacting the development of therapy agents, and market access in Brazil
- Get an analysis of Brazil’s manufacturing and outsourcing sector
Key Players
Table of Contents
Frequently Asked Questions
The Brazil pharmaceutical market was valued at $17.2 billion in 2021.
The key trends impacting the Brazil pharmaceutical market are industry trends and regulatory trends.
The top therapy areas in the Brazil pharmaceutical market are oncology, central nervous system, infectious disease, respiratory, cardiovascular, metabolic disorders, and immunology among others.
The key molecule types in the COVID-19 pipeline in Brazil are subunit vaccine, small molecule, inactivated vaccine, cell therapy, monoclonal antibody, peptide, vaccine, and mRNA vaccine.
Get in touch to find out about our multi-purchase discounts
reportstore@globaldata.com
Tel +44 (0) 20 7947 2960
Every customer’s requirement is unique. We understand that and can customize the report basis your exact research requirements pertaining to market insights, innovation insights, strategy and planning, and competitive intelligence. You can also avail the option of purchasing stand-alone sections of the report or request for a country specific report.
Still undecided about purchasing this report?
Testimonial
“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.
GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”
“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”
Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.
Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.